Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 547Carcinoma, Non-Small-Cell Lung 506Prostatic Neoplasms 332Colorectal Neoplasms 270Multiple Myeloma 266Neoplasms 260Leukemia, Myeloid, Acute 221Squamous Cell Carcinoma of Head and Neck 213Lung Neoplasms 206Neoplasm Metastasis 203Carcinoma, Hepatocellular 196Melanoma 172Triple Negative Breast Neoplasms 171Pancreatic Neoplasms 170Recurrence 152Ovarian Neoplasms 149Lymphoma 139Brain Neoplasms 132Glioblastoma 131Sarcoma 130Carcinoma, Renal Cell 126Leukemia, Lymphocytic, Chronic, B-Cell 124Head and Neck Neoplasms 124Stomach Neoplasms 122Lymphoma, Large B-Cell, Diffuse 122Rectal Neoplasms 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Myelodysplastic Syndromes 102Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

erdafitinib 1atezolizumab 1Tiragolumab 1Midazolam 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Urothelial Cancer × 1 year × Clear all
NCT02365597 2026-06-05

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Janssen Research & Development, LLC

Phase 2 Active not recruiting
239 enrolled 32 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT05645692 2026-04-29

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Hoffmann-La Roche

Phase 2 Active not recruiting
204 enrolled
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡